114 related articles for article (PubMed ID: 25757092)
1. Luotonin-A based quinazolinones cause apoptosis and senescence via HDAC inhibition and activation of tumor suppressor proteins in HeLa cells.
Venkatesh R; Ramaiah MJ; Gaikwad HK; Janardhan S; Bantu R; Nagarapu L; Sastry GN; Ganesh AR; Bhadra M
Eur J Med Chem; 2015 Apr; 94():87-101. PubMed ID: 25757092
[TBL] [Abstract][Full Text] [Related]
2. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Harms KL; Chen X
Cancer Res; 2007 Apr; 67(7):3145-52. PubMed ID: 17409421
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
5. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2.
Huang WY; Yang PM; Chang YF; Marquez VE; Chen CC
Biochem Pharmacol; 2011 Feb; 81(4):510-7. PubMed ID: 21114963
[TBL] [Abstract][Full Text] [Related]
7. Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects.
Janaki Ramaiah M; Naushad SM; Lavanya A; Srinivas C; Anjana Devi T; Sampathkumar S; Dharan DB; Bhadra MP
Gene; 2017 Sep; 627():379-386. PubMed ID: 28668345
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a series of small molecules as potent histone deacetylase inhibitors.
Zhang L; Wang X; Li X; Xu W
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):333-7. PubMed ID: 23534931
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells.
Liu PY; Chan JY; Lin HC; Wang SL; Liu ST; Ho CL; Chang LC; Huang SM
Mol Cancer Res; 2008 Jul; 6(7):1204-14. PubMed ID: 18644983
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration.
Wang S; Li X; Wei Y; Xiu Z; Nishino N
ChemMedChem; 2014 Mar; 9(3):627-37. PubMed ID: 24285590
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
13. Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer.
Parbin S; Shilpi A; Kar S; Pradhan N; Sengupta D; Deb M; Rath SK; Patra SK
Mol Biosyst; 2016 Jan; 12(1):48-58. PubMed ID: 26540192
[TBL] [Abstract][Full Text] [Related]
14. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases.
Seidel C; Schnekenburger M; Dicato M; Diederich M
Cancer Lett; 2014 Feb; 343(1):134-46. PubMed ID: 24080339
[TBL] [Abstract][Full Text] [Related]
16. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
17. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.
Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K
Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879
[TBL] [Abstract][Full Text] [Related]
18. Differential Regulation of Telomerase Reverse Transcriptase Promoter Activation and Protein Degradation by Histone Deacetylase Inhibition.
Qing H; Aono J; Findeisen HM; Jones KL; Heywood EB; Bruemmer D
J Cell Physiol; 2016 Jun; 231(6):1276-82. PubMed ID: 26505494
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
20. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
